H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Repare Therapeutics (RPTX – Research Report) today and set a price target of $54.00. The company's shares closed last Monday at $20.10, close to its 52-week low of $19.82. According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.9% and a 22.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Repare Therapeutics with a $48.17 average price target, a 138.6% upside from current levels. In a report released today, Bloom Burton also maintained a Buy rating on the stock with a $49.00 price target. See today’s analyst top recommended stocks >> The company has a one-year high of $46.44 and a one-year low of $19.82. Currently, Repare Therapeutics has an average volume of 179.3K. Based on the recent corporate insider activity of 209 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RPTX in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. Read More on RPTX: Disney vs. Comcast: Which Stock is a Better Pick? H.C. Wainwright Thinks TRACON Pharmaceuticals’ Stock is Going to Recover Cleveland-Cliffs Acquires Ferrous Processing and Trading Company for $775M AbbVie Stock: Price Seems Fair for Biopharmaceutical Play Southwest Airlines Cancels More than 1,800 Flights; Shares Plunge The post H.C. Wainwright Thinks Repare Therapeutics' Stock is Going to Recover appeared first on TipRanks Financial Blog.